Phaseline

Companies › Serum Institute of India

Serum Institute of India: clinical trials, targets and expected readouts

4 active drug programs in 7 registered trials: 4 Phase 2, 2 Phase 1, 1 Phase 3; Infectious disease; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cervavac
Quadrivalent human papillomavirus (qHPV) vaccine targeting HPV types 6, 11, 16, 18
–Phase 3Human Papillomavirus InfectionDec 2026
Pfs230D1-CRM197 + R21 with Matrix-M1
Recombinant malaria vaccine combining Pfs230D1 antigen (a sexual-stage antigen of Plasmodi
–Phase 2Prevention of Malaria Transmission and Clinical MalariaNov 2027
R21
Recombinant fusion protein of Plasmodium falciparum circumsporozoite protein (CSP) fused t
–Phase 2Prevention of Malaria Transmission and Clinical Malaria; Malaria,FalciparumNov 2027
Recombinant Poliomyelitis Vaccine (rPV)
Recombinant poliomyelitis virus-like particles (VLP)
–Phase 1Polio ImmunityNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07688369Recombinant Poliomyelitis Vaccine (rPV)Phase 1Polio ImmunityInfectious diseaseNov 2026
NCT06281119CervavacPhase 3Human Papillomavirus InfectionInfectious diseaseDec 2026
NCT07183371R21Phase 2Malaria,FalciparumInfectious diseaseMar 2027
NCT06958198R21Phase 1Malaria,FalciparumInfectious diseaseMar 2027
NCT07147400Pfs230D1-CRM197 + R21 with Matrix-M1Phase 2Prevention of Malaria Transmission and Clinical MalariaInfectious diseaseNov 2027
NCT07147400Pfs230D1-CRM197 + R21 with Matrix-M1Phase 2Prevention of Malaria Transmission and Clinical MalariaInfectious diseaseNov 2027
NCT07147400R21Phase 2Prevention of Malaria Transmission and Clinical MalariaInfectious diseaseNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CanSino Biologics Eveliqure Biotechnologies Sanaria Brii Biosciences SIGA Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.